BioSpace News Archive

Forecast to 2030,’ thoroughly examines the Throat Cancer industry to provide essential data & information for the targeted readers.

The growth of the capillary and venous blood sampling devices market, which is estimated to reach a value of US$ 2.4 Bn by 2030.

The global ornithine transcarbamylase (OTC) deficiency treatment market was valued at US$ 600 Mn in 2021. It is projected to expand at a CAGR of 4% from 2022 to 2030.

As a result of recent research revealing that a significant number of colorectal cancer patients with actionable variants are missed under previous genetic testing guidelines, the National Comprehensive Cancer Network (NCCN) announced new guidelines calling for testing to be available to all patients diagnosed with colorectal cancer.

Genmab A/S announced that it is improving its 2022 financial guidance published on May 11, 2022.

Applied DNA Sciences, Inc. announced the closing of its previously announced public offering of 3,000,000 shares of its common stock, together with Series A warrants to purchase up to 3,000,000 shares of its common stock and Series B warrants to purchase up to 3,000,000 shares of its common stock at a combined offering price to the public of $4.00 per share and associated warrants, priced at a premium to market under Nasdaq rules.

Avinger, Inc. announced the closing of its previously announced registered direct and private placement offerings priced at-the-market under Nasdaq rules, including the issuance and sale of 700,000 shares of common stock and 784,019 pre-funded warrants in the registered direct offering and 1,369,864 pre-funded warrants in the private placement.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2022 financial results.

Opiant Pharmaceuticals, Inc. announced that the Biomedical Advanced Research and Development Authority has awarded an additional approximately $2.1 million to support OPNT003, nasal nalmefene, for the treatment of opioid overdose.

– RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, reported financial results for the three and six months ended June 30, 2022.